Trials / Completed
CompletedNCT04943900
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
A Phase 1 Study of BMS-986416 Alone and in Combination With Nivolumab in Select Solid Tumors
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 67 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986416 | Specified dose on specified days |
| DRUG | Nivolumab | Specified dose on specified days |
Timeline
- Start date
- 2021-08-09
- Primary completion
- 2025-02-27
- Completion
- 2025-02-27
- First posted
- 2021-06-29
- Last updated
- 2025-04-09
Locations
19 sites across 7 countries: United States, Argentina, Belgium, Canada, Chile, Japan, Netherlands
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04943900. Inclusion in this directory is not an endorsement.